In an industry where time-to-market is critical, a strategic collaboration between AGC Biologics, a global leader in biopharmaceutical development, and BioConnection, an aseptic filling expert, may be the key to unlocking faster pathways from laboratory to patient. As biotechnology firms grapple with the ever-evolving legal and logistical challenges of bringing life-saving treatments to market, this partnership presents a promising solution. By integrating the skilled services that span from the initial biopharmaceutical drug substance and product development to the final manufacturing stage, the alliance aims to create a seamless journey from gene to vial.This strategic agreement comes at a crucial moment, with the impending US BIOSECURE Act, which places new constraints on the use of biotechnological services from certain overseas entities. By offering an end-to-end service that keeps pace with legislative shifts, AGC Biologics and BioConnection provide a compelling option for biopharmaceutical developers who must navigate a complex and changing regulatory environment. Combining AGC’s extensive network across Japan, the US, and Europe with BioConnection’s bespoke aseptic filling capabilities, the alliance is poised to deliver secure and robust solutions throughout the drug development lifecycle.
